CD44 and neoplasm: Recent literature has been conducted which shows that CD44 targeted nanocarriers can enhance the delivery and effectiveness of checkpoint inhibitors, including anti-PD-1, by specifically targeting CD44-overexpressing tumor cells which are frequently resistant to traditional immune checkpoint blockage treatments (17, 103–105).